Literature DB >> 30613017

[Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro].

Qiaohua Zhu1, Meihua Luo1, Chengyu Zhou1, Zhixian Chen1, Wei Huang1, Jiangyuan Huang1, Shufeng Zhao1, Xinfa Yu1.   

Abstract

OBJECTIVE: To investigate the effect of danusertib (Danu), an inhibitor of Aurora kinase, on the proliferation, cell cycle, apoptosis, and autophagy of hepatocellular carcinoma HepG2 cells and explore the underlying mechanisms.
METHODS: MTT assay was used to examine the effect of Danu on the viability of HepG2 cells to determine the IC50 of Danu. The effect of Danu on cell cycle distribution, apoptosis and autophagy were determined using flow cytometry. Western blotting was used to detect the expressions of the proteins related to cell cycle, apoptosis and autophagy. Chloroquine was used to suppress Danuinduced autophagy to test the apoptosis-inducing effect of Danu.
RESULTS: Danu significantly inhibited the proliferation of HepG2 cells with IC50 of 39.4 μmol and 14.4 μmol at 24 h and 48 h, respectively. Danu caused cell cycle arrest in G2/M phase in HepG2 cells and led to polyploidy accumulation via up-regulating the expressions of p53 and p21 and down-regulating the expressions of cyclin B1 and DC2. Danu also caused apoptosis of HepG2 cells through up-regulating the expressions of Bax, Puma, cleaved caspase-3, cleaved caspase-9, cleaved PARP and cytochrome C and down-regulating the expressions of Bcl-xl and Bcl-2. Danu induced autophagy via activating AMPK signaling and inhibiting PI3K/PTEN/AKT/mTOR axis, and inhibition of Danu-induced autophagy with chloroquine enhanced the pro-apoptotic effect of Danu.
CONCLUSIONS: Danu inhibits cell proliferation and induces cell cycle arrest in G2/M phase, apoptosis and cytoprotective autophagy in HepG2 cells.

Entities:  

Keywords:  Aurora kinase; apoptosis; autophagy; cell cycle arrest; danusertib; hepatocellular carcinoma

Mesh:

Substances:

Year:  2018        PMID: 30613017      PMCID: PMC6744215          DOI: 10.12122/j.issn.1673-4254.2018.12.13

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  36 in total

1.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

Review 2.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

Review 3.  Late mitotic functions of Aurora kinases.

Authors:  Olga Afonso; Ana C Figueiredo; Helder Maiato
Journal:  Chromosoma       Date:  2016-04-22       Impact factor: 4.316

Review 4.  Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

Authors:  Jean-Luc Raoul; Masatoshi Kudo; Richard S Finn; Julien Edeline; Maria Reig; Peter R Galle
Journal:  Cancer Treat Rev       Date:  2018-05-26       Impact factor: 12.111

5.  A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.

Authors:  Qiaohua Zhu; Meihua Luo; Chengyu Zhou; Zhiwei Zhou; Zhixu He; Xinfa Yu; Shufeng Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

6.  Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.

Authors:  P Schöffski; B Besse; T Gauler; M J A de Jonge; G Scambia; A Santoro; C Davite; M G Jannuzzo; A Petroccione; J-P Delord
Journal:  Ann Oncol       Date:  2014-12-08       Impact factor: 32.976

Review 7.  Aurora kinase inhibitors as anti-cancer therapy.

Authors:  Warren Lok; Rhonda Q Klein; Muhammad Wasif Saif
Journal:  Anticancer Drugs       Date:  2010-04       Impact factor: 2.248

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 10.  Aurora kinases: novel therapy targets in cancers.

Authors:  Anqun Tang; Keyu Gao; Laili Chu; Rui Zhang; Jing Yang; Junnian Zheng
Journal:  Oncotarget       Date:  2017-04-04
View more
  2 in total

1.  A gene module identification algorithm and its applications to identify gene modules and key genes of hepatocellular carcinoma.

Authors:  Yan Zhang; Zhengkui Lin; Xiaofeng Lin; Xue Zhang; Qian Zhao; Yeqing Sun
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

2.  Resveratrol contributes to the inhibition of liver fibrosis by inducing autophagy via the microRNA‑20a‑mediated activation of the PTEN/PI3K/AKT signaling pathway.

Authors:  Lili Zhu; Qiuju Mou; Yinghui Wang; Zixin Zhu; Mingliang Cheng
Journal:  Int J Mol Med       Date:  2020-10-09       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.